Oncotelic Therapeutics OTLC Stock
Oncotelic Therapeutics Price Chart
Oncotelic Therapeutics OTLC Financial and Trading Overview
| Oncotelic Therapeutics stock price | 0.05 USD |
| Previous Close | 0.05 USD |
| Open | 0.05 USD |
| Bid | 0.05 USD x 6860000 |
| Ask | 0.05 USD x 1000000 |
| Day's Range | 0.05 - 0.05 USD |
| 52 Week Range | 0.02 - 0.11 USD |
| Volume | 170.24K USD |
| Avg. Volume | 278.6K USD |
| Market Cap | 22.22M USD |
| Beta (5Y Monthly) | -0.317 |
| PE Ratio (TTM) | 0.084745765 |
| EPS (TTM) | 0.59 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
OTLC Valuation Measures
| Enterprise Value | 35.4M USD |
| Trailing P/E | 0.084745765 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 1.05 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.084317036 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Oncotelic Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.317 |
| 52-Week Change | 25.00% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 0.11 USD |
| 52 Week Low | 0.02 USD |
| 50-Day Moving Average | 0.05 USD |
| 200-Day Moving Average | 0.07 USD |
OTLC Share Statistics
| Avg. Volume (3 month) | 278.6K USD |
| Avg. Daily Volume (10-Days) | 217.69K USD |
| Shares Outstanding | 444.5M |
| Float | 228.43M |
| Short Ratio | 8.04 |
| % Held by Insiders | 48.44% |
| % Held by Institutions | 0% |
| Shares Short | 662.75K |
| Short % of Float | 2.50% |
| Short % of Shares Outstanding | 2.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -1.40% |
| Return on Equity (ttm) | 183.48% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | 247.38M USD |
| Diluted EPS (ttm) | 0.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 63.61K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 14.31M USD |
| Total Debt/Equity (mrq) | 5.46 USD |
| Current Ratio (mrq) | 0.112 |
| Book Value Per Share (mrq) | 0.593 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1558433 USD |
| Levered Free Cash Flow (ttm) | -1516163 USD |
Profile of Oncotelic Therapeutics
| Country | United States |
| State | CA |
| City | Agoura Hills |
| Address | 29397 Agoura Road |
| ZIP | 91301 |
| Phone | 650 635 7000 |
| Website | https://www.oncotelic.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 38 |
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
Q&A For Oncotelic Therapeutics Stock
What is a current OTLC stock price?
Oncotelic Therapeutics OTLC stock price today per share is 0.05 USD.
How to purchase Oncotelic Therapeutics stock?
You can buy OTLC shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oncotelic Therapeutics?
The stock symbol or ticker of Oncotelic Therapeutics is OTLC.
Which industry does the Oncotelic Therapeutics company belong to?
The Oncotelic Therapeutics industry is Biotechnology.
How many shares does Oncotelic Therapeutics have in circulation?
The max supply of Oncotelic Therapeutics shares is 444.5M.
What is Oncotelic Therapeutics Price to Earnings Ratio (PE Ratio)?
Oncotelic Therapeutics PE Ratio is 0.08474577 now.
What was Oncotelic Therapeutics earnings per share over the trailing 12 months (TTM)?
Oncotelic Therapeutics EPS is 0.59 USD over the trailing 12 months.
Which sector does the Oncotelic Therapeutics company belong to?
The Oncotelic Therapeutics sector is Healthcare.